Hudson Bay Capital Management’s Pliant Therapeutics PLRX Stock Holding History

Hudson Bay Capital Management’s Portfolio PLRX Stock Details PLRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-15,710	Closed	-$18.2K	–	1588
2025 Q2	$18.2K	Sell	15,710 -69,290	-82%	-$97.9K	﹤0.01%	1314
2025 Q1	$115K	Buy	85,000 +27,500	+48%	+$167K	﹤0.01%	1165
2024 Q4	$757K	Sell	57,500 -42,500	-43%	-$580K	﹤0.01%	786
2024 Q3	$1.12M	Hold	100,000	–	–	﹤0.01%	660
2024 Q2	$1.07M	Buy	100,000 +30,600	+44%	+$394K	0.01%	597
2024 Q1	$1.03M	Buy	69,400 +24,400	+54%	+$402K	0.01%	539
2023 Q4	$815K	Buy	+45,000	New	+$684K	0.01%	535
2023 Q3	–	Sell	-19,700	Closed	-$357K	–	922
2023 Q2	$357K	Buy	+19,700	New	+$466K	﹤0.01%	642

Other funds holding PLRX

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

BOCH

Blue Owl Capital Holdings New York $372M AUM 78.25% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

Hudson Bay Capital Management's PLRX Position: Q3 2025 in Review

Hudson Bay Capital Management sold out of Pliant Therapeutics (PLRX) in Q3 2025, closing a stake of 15,710 shares — an estimated $18.2K sold.

Hudson Bay Capital Management first reported a position in PLRX in Q2 2023 and held it in 8 quarters. The position peaked at $1.12M in Q3 2024. 99 funds tracked by Wall St. Rank hold PLRX as of Q3 2025.

Hudson Bay Capital Management reported no remaining Pliant Therapeutics position as of Q3 2025 after selling out during the quarter.
Hudson Bay Capital Management sold 15,710 Pliant Therapeutics shares in Q3 2025, an estimated $18.2K.
Hudson Bay Capital Management first reported a position in Pliant Therapeutics in Q2 2023 and held it in 8 quarters.
Hudson Bay Capital Management's Pliant Therapeutics position peaked at $1.12M in Q3 2024.
99 funds tracked by Wall St. Rank held Pliant Therapeutics as of Q3 2025.

Based on Hudson Bay Capital Management's 13F filing for Q3 2025, filed 13 Nov 2025.